Introduction
============

Dengue is the commonest human arboviral disease worldwide, with an estimated 50--100 million cases occurring annually throughout the tropics and subtropics ([@ref-40]; [@ref-52]). Dengue results from human infection with one of four related serotypes of dengue virus (DENV-1-4) ([@ref-16]). In the five years leading up to and including the current study (2018), all four serotypes circulated in the region of South America surrounding Paraguay ([Fig. 1](#fig-1){ref-type="fig"}), which reports among the highest annual incidence rates of dengue on the continent ([@ref-8]; [@ref-14];[@ref-32]). Over the past decade, DENV-1 has circulated in Paraguay in all but one year, and it has been predominant since 2015 ([@ref-9]; [@ref-32]). Despite significant declines in dengue incidence throughout the Americas following the 2015--2016 Zika virus (ZIKV) epidemic, Paraguay experienced large numbers of dengue cases in 2016 and again in 2018 ([@ref-32]; [@ref-35]). These data suggest that arboviral epidemiology may be relatively unique in Paraguay, which is located at the southern boundary of the DENV-endemic region in the Americas ([@ref-2]; [@ref-40]; [@ref-52]). However, relatively little data has been published on dengue in the country, and the majority of available data has come either from hospitalized pediatric cases or from international studies with only a subset of patients from Paraguay ([@ref-17]; [@ref-25]; [@ref-26]; [@ref-38]).

![Map of South America highlighting Paraguay and surrounding countries.\
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Symptomatic DENV infections classically present as an acute fever with myalgias and rash ([@ref-16]; [@ref-52]). However, patients can develop a wide array of signs and symptoms, which limits the accuracy of a clinical diagnosis based on exam findings and results of routine laboratory testing ([@ref-15]; [@ref-31]; [@ref-36]; [@ref-49]). In addition, dengue manifests differently among children and adults, and factors associated with dengue cases and severe disease in a pediatric population may not be applicable in older patients ([@ref-15]; [@ref-18]; [@ref-21]). The differential diagnosis for dengue includes arboviral pathogens, such as chikungunya virus (CHIKV) and Zika virus (ZIKV), and local endemic diseases, such as leptospirosis, which may all cause an indistinguishable clinical picture ([@ref-39]; [@ref-49]). Accurate diagnosis in the acute phase relies upon the availability of specific laboratory tests, which for DENV include molecular methods and nonstructural protein 1 (NS1) antigen detection. Anti-DENV IgM detection in acute-phase samples provides a presumptive diagnosis ([@ref-34]; [@ref-52]). As dengue can progress to severe disease, including plasma leakage, hemorrhage, and shock, ideal testing algorithms would not only detect DENV infections but also provide prognostic information.

The primary objective of the current study was to characterize DENV infections in the Central Department of Paraguay and the metropolitan area of Asunción. This region annually accounts for ∼2/3 of dengue cases in Paraguay and also reported Zika cases in 2016. Multiplex molecular testing, NS1 antigen detection and serological methods were implemented to confirm cases identified using a broad clinical case definition. We then sought to evaluate factors associated with dengue cases and the need for hospitalization in a predominantly adult patient population.

Materials & Methods
===================

Ethics statement
----------------

The study protocol was reviewed and approved by the Scientific and Ethics Committee of the Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción (IICS-UNA, IRB00011984), and the Emory University Institutional Review Board (IRB00000569). Written informed consent was obtained from all subjects. Children older than six years of age provided assent.

Patient population and clinical samples
---------------------------------------

Patients of all ages were enrolled from January to May 2018 if they presented with an acute illness (≤8 days) defined by two or more of the following: fever (measured or subjective), red eyes, rash, joint pain involving more than one joint, and/or diffuse muscle pain. Patients with fever and no other localizing signs or symptoms were included. Day 1 was defined as the first day of symptoms. Exclusion criteria included dysuria or malodorous urine, cellulitis/skin abscess, vomiting and/or a productive cough. Patients were enrolled at in the Emergency Care Clinic at Hospital Villa Elisa and at IICS-UNA, both located in metro Asunción. The Emergency Care Clinic serves an ambulatory urgent care patient population; patients may be assigned to observation at Hospital Villa Elisa or referred to an inpatient facility that can provide a higher level of care. Serum was collected during the acute visit, aliquoted and stored at −80 °C until use. The results from hemograms, performed as part of routine care, were obtained by chart review. Data was included in this study if the hemogram was obtained on the day of the study visit ±1 day.

Molecular detection
-------------------

RNA was extracted from 140 µL of serum into 60 µL of elution buffer with the QIAamp Viral RNA Mini Kit (Qiagen, Germantown, MD, USA). All samples were tested for ZIKV, CHIKV and DENV by real-time RT-PCR (rRT-PCR) using a validated and published multiplex assay (the ZCD assay) as previously described ([@ref-48]). DENV serotype and viral load were determined with a DENV multiplex assay using a published protocol ([@ref-46]; [@ref-47]). Samples that tested negative in the ZCD assay were tested for RNase P to confirm successful extraction and the absence of inhibitors ([@ref-45]). All rRT-PCR testing was performed at IICS-UNA.

Serological assays
------------------

All serum samples were test for DENV NS1 antigen and anti-DENV IgM and IgG using the STANDARD Q Dengue Duo assay (SD Biosensor, Suwon, South Korea). Results were read initially at 15 or up to 20 min, according to manufacturer recommendations. One hundred fifty-six samples were tested for anti-ZIKV IgG using the ZIKVG. CE kit (Diagnostic Bioprobes, Milan, Italy), which detects antibodies directed against the ZIKV NS1 antigen. Given a limited supply of anti-ZIKV IgG kits, a mixture of samples was selected for testing. This included dengue cases (*n* = 76) and non-dengue cases (*n* = 80), as well as include patients with anti-DENV IgG (*n* = 58) and without (*n* = 98). Assays were performed according to manufacturer recommendations.

Definitions
-----------

Dengue cases were defined by either the detection of (1) DENV RNA in serum using the ZCD assay with confirmation in the DENV multiplex assay, or (2) both NS1 and anti-DENV IgM. This conservative definition was used to ensure the accuracy of dengue-case calls in the absence of paired acute and convalescent sera for confirmatory serological testing. This definition also allowed us to evaluate the performance of the STANDARD Q DENV NS1 assay, for which there was no prior published data. The sensitivity and specificity of individual diagnostics were calculated in reference to positive and negative cases from this composite definition.

Statistics
----------

Basic statistical analyses were performed using Excel software (Microsoft, Redmond, WA). Univariate analyses and multiple linear regression analyses were performed using GraphPad Prism, version 8.0.1 (GraphPad, San Diego, CA, USA). Categorical variables were compared using Fisher's exact test. Age, day of illness, and continuous laboratory variables were compared by t test. Viral load comparisons were performed using non-parametric tests (Mann--Whitney with 2 groups; Kruskal-Wallis for 3 or more groups). Binary logistic regression analysis was performed using SPSS (IBM, Armonk, NY). Model fit was assessed by comparing −2 log likelihood statistics.
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###### DENV diagnostic test results according to test method.

DENV viral load is shown for rRT-PCR positive samples within a given category.
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                                  **Composite definition**                                                          
  ------------------------------- -------------------------- ------------------------------------------ ----------- -------------
  Combination of methods                                                                                             
  rRT-PCR                         28 (23.5)                  --                                         3.1 (1.5)   6.10 (1.69)
  rRT-PCR and NS1                 60 (50.4)                  --                                         3.2 (1.4)   7.85 (1.27)
  rRT-PCR, NS1, and IgM           21 (17.7)                  --                                         5.3 (1.3)   5.40 (1.19)
  rRT-PCR and IgM                 6 (5.0)                    --                                         6.7 (1.0)   3.58 (0.22)
  NS1 and IgM                     4 (3.4)                    --                                         7.2 (0.1)   --
  Negative                        --                         112                                        3.2 (1.6)   --
  Positives according to method                                                                                      
  rRT-PCR                         115 (96.6)                 --                                         3.7 (1.7)   
  NS1                             85 (71.4)                  4 (3.6)[^b^](#table-1fn2){ref-type="fn"}   3.9 (1.8)   
  IgM                             31 (26.1)                  7 (6.2)[^b^](#table-1fn2){ref-type="fn"}   5.6 (1.5)   

**Notes.**

sdstandard deviation

Reported as log~10~ copies/mL of serum.

Specificities were 96.4% (NS1) and 93.8% (IgM).

Results
=======

Between January and May 2018, we enrolled 231 patients who met inclusion criteria, including 119 (51.5%) dengue cases and 112 (48.5%) non-dengue cases. No acute cases of ZIKV or CHIKV were detected. Of the dengue cases, 115 (96.6%) tested positive by rRT-PCR and 4 additional cases (3.4%) were positive for DENV NS1 and anti-DENV IgM ([Table 1](#table-1){ref-type="table"}). All cases tested positive by rRT-PCR through day-of-illness 6 (*n* = 104), with rates of detection declining on days 7 (7/10, 70%) and 8 (4/5, 80%; [Fig. 2](#fig-2){ref-type="fig"}). For the NS1 assay, the overall sensitivity and specificity were 71.4% and 96.4%, respectively ([Table 1](#table-1){ref-type="table"}). Although there appeared to be an increase in NS1 sensitivity over the first 5 days of illness, this was not statistically significant (*p* = 0.208, day 5 vs. day 1--2; [Fig. 2](#fig-2){ref-type="fig"}). The overall sensitivity and specificity of anti-DENV IgM detection were 26.1% and 93.8%, respectively. The sensitivity of IgM detection increased from 0% on days 1--2 to 90% on day 7 (*p* \< 0.001).

![Sensitivity of rRT-PCR, NS1, and IgM for dengue based on day of illness at presentation.](peerj-07-7852-g002){#fig-2}

DENV serotype was determined in all 115 rRT-PCR-positive cases, with DENV-1 identified in 109/115 (94.8%) cases and 3 cases (2.6%) each of DENV-2 and DENV-4. No co-infections were detected. DENV-1 serum viral loads negatively correlated with day of illness at presentation ([Fig. 3A](#fig-3){ref-type="fig"}), but too few data points were available for DENV-2 and -4 to draw meaningful conclusions. DENV viral load was also associated with NS1 detection: viral loads were significantly higher in samples with detectable NS1 (median 7.7 log~10~ copies/mL, IQR 5.8--8.6) compared to those in which NS1 was not detectable (median 5.6 log~10~ copies/mL, IQR 3.6--7.2; *p* \< 0.001; [Fig. S1](#supp-2){ref-type="supplementary-material"}).

![DENV viral load at presentation based on day of illness and antibody status.\
DENV-1 viral load by day of illness at presentation (A). Viral loads are shown for individual samples; bars display the mean and 95% CI. Six patients had infections with DENV-2 (*n* = 3) or DENV-4 (*n* = 3), which are not displayed. DENV viral load at presentation decreases in a stepwise manner among individuals with anti-ZIKV IgG, anti-DENV IgG, or both (B). Results were significant by ANOVA for both analyses, *p* \< 0.0001.](peerj-07-7852-g003){#fig-3}

Anti-DENV and anti-ZIKV IgG results were available for 156 patients, including 76 dengue cases (48.7%). 58 patients (37.2%) tested positive for anti-DENV IgG and 49 (31.4%) tested positive for anti-ZIKV IgG, with 32 patients (20.5%) positive for both. The viral load among dengue cases declined in a stepwise manner among patients with anti-ZIKV IgG, anti-DENV IgG, or both ([Fig. 3B](#fig-3){ref-type="fig"}, *p* \<  0.001 for the trend). In a multivariable model that included day of illness at presentation and patient age, DENV serum viral load was 1.3 log~10~ copies/mL lower among patients with detectable anti-DENV IgG compared to patients without anti-DENV IgG (*p* \<  0.001, [Table S1](#supp-3){ref-type="supplementary-material"}). Similarly, serum viral load was 0.7 log~10~ copies/mL lower among patients with anti-ZIKV IgG directed against NS1 (*p* = 0.047).

Among dengue cases, DENV NS1 detection was also associated with IgG status. Patients with anti-DENV IgG were significantly less likely to have detectable NS1 (20/36 (55.6%) vs. 65/83 (78.3%); OR 0.3, 95% CI \[0.1--0.8\]). However, when we controlled for the detection of IgG against ZIKV NS1, the OR for NS1 detection among dengue cases with anti-ZIKV IgG was 0.1 (95% CI \[0.0--0.3\]) and the association with anti-DENV IgG was no longer significant (OR 1.0, 95% CI \[0.3--3.1\]; [Table S2](#supp-4){ref-type="supplementary-material"}).

Epidemiologic characteristics
-----------------------------

The epidemiologic characteristics of the patient population are shown in [Table 2](#table-2){ref-type="table"}. This was predominantly an adult population, with only 11 participants \<18 years of age at study entry (4.8%). Dengue cases occurred throughout the study period ([Fig. S2](#supp-2){ref-type="supplementary-material"}) and were similar to non-dengue cases for the majority of epidemiological variables analyzed. Most patients reported living in a house or an apartment (157/188 for which data was available, 83.5%), but 31 patients reported "other" for housing without providing further detail. The odds of dengue in this population were significantly higher than among patients with a different living arrangement (OR 2.9, 95% CI \[1.3--7.0\]). Only 10.6% of our patients (21/199) reported having screens on their windows, though 79.2% of patients had air conditioning (156/197). The percentage of dengue cases among patients with neither screens nor air conditioning (19/37, 51.4%) was similar to that of patients with screens, air conditioning, or both (79/161, 49.1%; OR 1.1, 95% CI \[0.5--2.2\]).
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###### Epidemiologic data on patients presenting with an acute febrile illness who tested positive or negative for DENV.
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  **Factor**[^a^](#table-2fn2){ref-type="fn"}                           **Total**      **Dengue cases**   **Non-dengue**                               *p*-value
  --------------------------------------------------------------------- -------------- ------------------ -------------------------------------------- -----------
  Patients                                                              231 (100)      119 (100)          112 (100)                                    
  Gender, female                                                        128 (55.4)     63 (52.9)          65 (58.0)                                    
  Age, mean (sd)                                                        31.94 (14.3)   31.3 (15.0)        32.6 (13.6)                                  
  Clinical Site                                                                                                                                        
  Hospital Villa Elisa                                                  185 (80.1)     100 (84.0)         85 (75.9)                                    
  IICS-UNA                                                              46 (19.9)      19 (16.0)          27 (24.1)                                    
  Department                                                                                                                                           
  Central                                                               209 (90.5)     109 (91.6)         100 (89.3)                                   
  Capital                                                               20 (8.7)       8 (6.7)            12 (10.7)                                    
  Residence                                                                                                                                            
  House                                                                 149 (79.3)     70 (74.4)          79 (84.0)                                    
  Apartment                                                             8 (4.3)        2 (2.1)            6 (6.4)                                      
  Other                                                                 31 (16.5)      22 (23.4)          9 (9.6)                                      0.017
  Screens                                                               21 (10.6)      10 (10.0)          11 (11.1)                                    
  Air-conditioning                                                      156 (79.2)     76 (78.4)          80 (80.0)                                    
  Running water                                                         199 (98.0)     97 (97.0)          102 (99.0)                                   
  Water storage                                                         18 (8.8)       8 (8.0)            10 (9.5)                                     
  Exposures                                                                                                                                            
  Travel in the last month                                              52 (25.0)      22 (20.8)          30 (29.4)                                    
  Work or school outside of the home                                    152 (80.4)     68 (73.9)          84 (86.6)                                    
  Work or school outdoors                                               24 (55.8)      11 (57.9)          13 (54.2)                                    
  Medical History                                                                                                                                      
  Received yellow fever vaccine                                         71 (42.0)      31 (37.3)          40 (46.5)                                    
  Years since vaccination, mean (sd)[^c^](#table-2fn4){ref-type="fn"}   7.6 (4.1)      8.5 (3.7)          6.8 (4.3)                                    
  Personal history of dengue                                            78 (34.2)      29 (24.6)          49 (44.6)[^d^](#table-2fn5){ref-type="fn"}   0.002

**Notes.**

Abbreviationsnnumbersdstandard deviation

Unless otherwise specific, all values presented as n (% of patients with a response recorded).

OR for dengue for patients reporting "other", 2.9 (95% CI \[1.3--7.0\]).

Year of YF vaccination was available for 52 patients (24 DENV-positive, 28 DENV-negative).

OR for dengue in patients who reported a history of dengue, 0.4 (95% CI \[0.2--0.7\]).

A subset of patients self-reported having been vaccinated against yellow fever virus (YFV). The odds of having a dengue case were lower among patients who had received the YFV vaccine compared to those who had not (OR 0.6; 0.4--1.2), and more time had elapsed since vaccination among dengue cases. However, these trends did not reach statistical significance (*p* = 0.15). Receipt of the YFV vaccine did not increase the need for hospitalization among dengue cases.

Clinical presentation
---------------------

Patient symptoms at presentation are shown in [Table 3](#table-3){ref-type="table"}. The majority of patients met inclusion criteria with fever plus one additional symptom in the study definition, most commonly muscle pain (198/225, 88.0%) and/or joint pain (172/221, 77.8%). Only 11 patients (4.8%) had fever and no other localizing sign or symptom (six dengue cases), and eight patients (3.5%) were enrolled that did not have fever (one dengue case). Patients who reported red eyes were significantly more likely to have dengue (OR 2.1; 95% CI \[1.2--3.6\]) and those with a sore throat were significantly less likely to have dengue (OR 0.5; 95% CI \[0.3--0.8\]; [Table 3](#table-3){ref-type="table"}). Although a reported headache increased the odds of having dengue, this did not reach statistical significance (OR 2.3; 95% CI \[1.0--5.5\]), and headache was very common overall. Other symptoms occurred with similar frequency in the two groups, and no combination of symptoms accurately differentiated between dengue and non-dengue cases.
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###### Symptoms and laboratory findings among patients with and without dengue.
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  **Factor**[^a^](#table-3fn2){ref-type="fn"}   **Total**          **Dengue cases**   **Non-dengue**     OR (95% CI)[^b^](#table-3fn3){ref-type="fn"}   *p*-value
  --------------------------------------------- ------------------ ------------------ ------------------ ---------------------------------------------- -----------
  Patients                                      231 (100)          119 (100)          112 (100)                                                         
  Day of symptoms, mean (sd)                    3.9 (2.5)          4.1 (1.9)          3.7 (3.0)                                                         
  *Symptoms and signs at presentation*                                                                                                                  
  Fever                                         221 (96.5)         117 (99.2)         104 (93.7)                                                        
  Headache                                      206 (89.6)         111 (93.3)         95 (85.6)          2.3 (1.0--5.5)                                 0.083
  Retro-orbital pain                            94 (40.9)          53 (44.5)          41 (36.9)                                                         
  Muscle pain                                   198 (88.0)         99 (86.8)          99 (89.2)                                                         
  Joint pain                                    172 (77.8)         92 (80.7)          80 (74.8)                                                         
  Nausea                                        142 (61.7)         73 (61.3)          69 (62.2)                                                         
  Malaise                                       119 (51.7)         62 (52.1)          57 (51.4)                                                         
  Red eyes                                      99 (45.0)          61 (51.5)          38 (35.8)          2.1 (1.2--3.6)                                 0.010
  Abdominal pain                                95 (41.3)          51 (42.9)          44 (39.6)                                                         
  Vomiting                                      73 (31.7)          41 (34.5)          32 (28.8)                                                         
  Diarrhea                                      66 (28.7)          31 (26.1)          35 (31.5)                                                         
  Shortness of breath                           64 (27.8)          36 (30.3)          28 (25.2)                                                         
  Sore throat                                   61 (26.5)          23 (19.3)          38 (34.2)          0.5 (0.3--0.8)                                 0.011
  Cough                                         51 (22.2)          25 (21.0)          26 (23.4)                                                         
  Rash                                          52 (23.1)          32 (27.8)          20 (18.2)                                                         
  Edema                                         37 (16.2)          17 (14.3)          20 (18.0)                                                         
  Bleeding                                      32 (13.9)          20 (16.8)          12 (10.8)                                                         
  *Laboratory results*                                                                                                                                  
  Hemoglobin, g/dL, mean (sd)                   13.9 (1.5)         14.0 (1.5)         13.8 (1.5)                                                        
  Platelet count, per µL, mean (sd)             217,550 (89,921)   188,227 (82,079)   252,609 (86,650)                                                  \<0.001
  Thrombocytopenia, \<150,000 per µL            46 (22.8)          36 (32.7)          10 (10.9)          4.0 (1. 9-8.2)                                 \<0.001
  Leucocyte count, cells per mm^3^, mean (sd)   6090 (3686)        4158 (2023)        8401 (3899)                                                       \<0.001
  Leucopenia, \<4,000 cells per mm^3^           73 (36.1)          63 (57.3)          10 (10.9)          11.0 (5.1--22.2)                               \<0.001

**Notes.**

AbbreviationsCIconfidence intervalORodds ratiosdstandard deviation

Values presented as *n* (%) unless otherwise indicated, percentages were calculated based on the number of patients with data recorded for a particular variable.

OR of having a dengue case versus a non-dengue case.

Hemogram results are also shown in [Table 3](#table-3){ref-type="table"}. Patients with dengue had significantly lower platelet and leucocyte counts relative to non-dengue cases ([Fig. 4](#fig-4){ref-type="fig"}). Thrombocytopenia (\<150,000 per µL) and leucopenia (\<4,000 cells/mm^3^) were both significantly associated with DENV infections ([Table 3](#table-3){ref-type="table"}). However, patients with both findings were not at greater odds of having a DENV infection (OR 8.9; 95% CI \[3.4--23.0\]) than patients with leucopenia alone (OR 11.0, 95% CI \[5.1--22.2\]). Dengue cases had lower neutrophil and lymphocyte counts, but these occurred in proportion to the decrease in leucocyte counts (see [Supplemental Files](#supplemental-information){ref-type="supplementary-material"}, [Raw Data](#supplemental-information){ref-type="supplementary-material"}).

![Platelet (A) and leucocyte (B) counts at presentation among dengue cases (●) and non-dengue cases (▴).\
Bars represent means ±95% CI; population mean values are shown.](peerj-07-7852-g004){#fig-4}

Hospitalization
---------------

For the analysis of factors associated with hospitalization for dengue, we focused on cases that presented to Hospital Villa Elisa, as only 1/19 dengue cases (5.3%) at IICS-UNA required hospitalization. Of 100 dengue cases at Hospital Villa Elisa, 26 (26.0%) were hospitalized and one patient died ([Table 4](#table-4){ref-type="table"}). A number of clinical and laboratory findings were associated with hospitalization in univariate analysis. Rash and bleeding were more common among hospitalized cases. Admitted patients were significantly more likely to have detectable anti-DENV IgG and IgG against both DENV and ZIKV (anti-NS1). Despite the presence of anti-DENV IgG, viral load was significantly higher among admitted patients, but there was no difference in NS1 detection. In multivariate analysis, the best-fit model for predictors of hospitalization only included platelet count and day of illness, though the odds ratio for day of illness did not reach significance (OR 1.3, 95% CI \[0.9--1.8\]; [Table S3](#supp-5){ref-type="supplementary-material"}).
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###### Clinical history and test results among hospitalized and outpatient dengue cases at Hospital Villa Elisa.
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  **Patient factors**[^a^](#table-4fn2){ref-type="fn"}    **Total**          **Hospitalized**   **Outpatient**     **OR (95% CI)**[^b^](#table-4fn3){ref-type="fn"}   *p*-value
  ------------------------------------------------------- ------------------ ------------------ ------------------ -------------------------------------------------- -----------
  Patients                                                100 (100)          26 (100)           74 (100)                                                              
  *History and Clinical findings*                         ** **              ** **              ** **              ** **                                              ** **
  Gender, female, n (%)                                   52 (52.0)          12 (46.2)          40 (54.1)                                                             
  Age, mean (sd)                                          31.6 (14.5)        36.5 (20.0)        29.9 (11.6)                                                           0.044
  Day of illness                                          3.81 (1.84)        5.0 (2.4)          3.4 (1.4)                                                             \<0.001
  YFV vaccination                                         23/64 (35.9)       5/16 (31.2)        17/48 (35.4)                                                          
  Past dengue, per report                                 34/99 (34.3)       12/25 (48.0)       22/74 (28.6)       2.2 (0.9--5.5)                                     0.143
  Rash                                                    28/96 (29.2)       13/25 (52.0)       15/71 (21.1)       4.0 (1.5--10.0)                                    0.005
  Diarrhea                                                27/100 (27.0)      11/26 (42.3)       16/74 (21.6)       2.7 (1.0--6.9)                                     0.070
  Bleeding                                                18/100 (18.0)      10/26 (38.5)       8/74 (10.8)        5.2 (1.8--14.1)                                    0.006
  *Dengue test results*                                                                                                                                                
  rRT-PCR, positive                                       99 (99.0)          25 (96.2)          74 (100)                                                              
  Viral load, mean (sd)                                   6.44 (2.04)        6.76 (1.84)        5.51 (2.35)                                                           0.028
  NS1                                                     69 (69.0)          17 (65.4)          52 (78.4)          0.8 (0.3--2.0)                                     0.632
  IgM, anti-DENV                                          25 (25.0)          10 (38.5)          15 (20.3)          2.5 (1.0--6.6)                                     0.112
  IgG, anti-DENV                                          28 (28.0)          14 (53.9)          14 (18.9)          5.0 (1.9--12.2)                                    0.002
  IgG, anti-ZIKV                                          19/70 (27.1)       7/16 (43.8)        12/54 (22.2)       2.7 (0.9--8.1)                                     0.114
  IgG against both DENV and ZIKV                          13/67 (19.4)       7/13 (53.8)        6/54 (11.1)        9.3 (2.2--36.3)                                    0.002
  *Laboratory results*[^c^](#table-4fn4){ref-type="fn"}   * *                * *                * *                * *                                                * *
  Hemoglobin, g/dL, mean (sd)                             14.1 (1.4)         14.0 (2.0)         14.2 (1.2)                                                            
  Platelet count, per µL, mean (sd)                       191,563 (85,951)   119,250 (77,402)   215,667 (74,749)                                                      \<0.001
  Thrombocytopenia, \<150,000 per µL                      31 (32.3)          18 (75.0)          13 (18.1)          13.6 (4.5--43.2)                                   \<0.001
  Leucocyte count, cells per mm^3^, mean (sd)             4167 (2135)        4814 (3209)        3952 (1604)                                                           0.087
  Leucopenia, \<4,000 cells per mm^3^                     55 (57.3)          13 (54.2)          42 (58.3)                                                             

**Notes.**

AbbreviationsCIconfidence intervalORodds ratiosdstandard deviation

Values presented as n (%) unless otherwise indicated.

OR for hospitalization versus outpatient care.

Lab results were available for 24 and 72 hospitalized cases and outpatients, respectively.

Discussion
==========

In the current study, we characterized a set of dengue cases in a primarily adult population that presented to outpatient facilities in metro Asunción. Dengue is a major public health problem in Paraguay, with adults accounting for a significant proportion of cases. At Hospital Villa Elisa, 58% of patients with an acute febrile illness were adults ≥20 years of age, and an additional 13% of patients were aged 15-19. While studies have demonstrated that the clinical presentation of dengue in adults may differ from that in children ([@ref-18]; [@ref-21]; [@ref-27]; [@ref-36]), less research has specifically evaluated factors that differentiate dengue from other causes of an acute febrile illness in the adult population ([@ref-7]; [@ref-15]; [@ref-27]). All but one dengue case in our study presented with fever and a high percentage of cases had headache, myalgia and/or arthralgia ([@ref-7]; [@ref-18]; [@ref-21]; [@ref-36]). These symptoms are consistent with the previous reports of dengue in adults, but were common among both dengue cases and non-dengue cases ([@ref-27]). The only two symptoms that were significantly associated with dengue in our population were red eyes and the absence of a sore throat. Red eyes have not been commonly associated with dengue ([@ref-7]), though one prior study found an association with DENV-1 ([@ref-53]). The absence of a sore throat has been associated with dengue in a previous series ([@ref-15]). However, this was only reported by 26.5% of our patients overall, which limits the utility of this finding in clinical practice.

In contrast to clinical findings, the results of general laboratory studies differed significantly between dengue cases and non-cases. Leucopenia and thrombocytopenia were associated with dengue (ORs 11.0 and 4.0, respectively), a finding that has been consistently documented in previous studies ([@ref-3]; [@ref-20]; [@ref-27]). However, patients with both findings did not have higher odds of dengue that those with leucopenia alone, which may have resulted from temporal differences in the development and resolution of these abnormalities ([@ref-3]). The nadir leucocyte counts occurred on days 5--6 after symptom onset, whereas platelet counts demonstrated a consistent decline through day 8 (see [Supplemental Files](#supplemental-information){ref-type="supplementary-material"}, [Raw Data](#supplemental-information){ref-type="supplementary-material"}). Many factors were significantly associated with hospitalization in univariate analyses but were also strongly correlated with one another (viral load, antibody status, platelet count, day of illness). Given the sample size, our ability to model all of these factors in logistic regression was limited, and admission decisions were likely based on the platelet count, which may have obscured the association between other factors and disease severity.

DENV infections were confirmed using a combination of methods, though all but four cases were positive by rRT-PCR (115/119, 96.6%). NS1 was detected in 71.4% of infections and proved specific for DENV (96.4%). Notably, the performance of this commercial NS1 kit has not been published, but results appeared similar to those reported for other rapid NS1 assays ([@ref-4]). Consistent with previous observations, viral loads were significantly higher among NS1-positive individuals ([@ref-10]; [@ref-11]; [@ref-12]; [@ref-43]). Both viral load and NS1 detection were significantly associated with the detection of anti-DENV IgG and anti-ZIKV IgG, which in this study was directed against the NS1 antigen. In an earlier study, ZIKV-specific neutralizing antibodies were not detected among a subset of our patients (A Rojas, 2019, unpublished data). As such, anti-ZIKV IgG identified by ELISA in the current study is favored to represent cross-reacting anti-DENV antibodies. In the subset of patients with results for both IgG assays, the presence of anti-ZIKV NS1 IgG accounted for virtually all false-negative NS1 results. Although such antibodies have been known to reduce NS1 detection in secondary cases ([@ref-19]; [@ref-22]; [@ref-23]), the pathophysiologic significance of anti-NS1 antibodies in human DENV infections remains unclear ([@ref-13]; [@ref-19]). We demonstrate that these antibodies can be detected in the acute-phase and, in combination with anti-DENV IgG, are more common among hospitalized dengue cases. These serologic findings combined with an elevated DENV viral load warrant further evaluation using standardized severity criteria ([@ref-51]; [@ref-52]).

Dengue cases were less likely to report living in a house or apartment (recorded as "other" in the study questionnaire). This was also observed in a seroprevalence study in Mexico where these patients reported a "shared" living arrangement ([@ref-33]). Other aspects of the home environment evaluated in our study did not differ between dengue and non-dengue cases. The absence of air conditioning and window screens did not appear to increase the risk for DENV infection. However, complete screening of the home and air conditioning have been associated with decreased vector indices and dengue incidence in other settings ([@ref-29]; [@ref-33]; [@ref-37]; [@ref-50]), and the addition of screens has been proposed as a means of DENV control through improvements to the built environment ([@ref-24]; [@ref-44]). Our findings may indicate that patients acquired DENV outside the home or that the use of these interventions is incomplete (e.g., non-intact screens, intermittent use of air conditioning). Determining the location of exposure will have important implications for DENV control efforts in metro Asunción.

Vaccination against YFV is not part of the routine schedule in Paraguay, and as a result, our patient population included a mixture of individuals who did or did not report receiving the vaccine. There was no evidence of increased risk from YFV vaccination for either incident dengue or the development of severe disease. These data are consistent with recent findings from Brazil where no association was found between severe dengue and receipt of the YFV vaccine ([@ref-28]).

DENV-1 was the predominant serotype identified in the current study. This is consistent with recent DENV epidemiology in Paraguay but precluded a comparison of symptoms caused by each serotype. DENV-1 is less commonly associated with severity than DENV-2, though severe and debilitating illness still occurs ([@ref-1]; [@ref-27]; [@ref-42]). Clinical findings in our patients appear more consistent with dengue in adults rather than dengue caused specifically by DENV-1, which is often associated with lower rates of arthralgia and myalgia ([@ref-6]; [@ref-30]; [@ref-41]; [@ref-53]). An additional limitation to the study is that we were unable to evaluate the performance of the clinical case definition for different arboviral infections, and in particular ZIKV infections that may not present with fever ([@ref-5]). Finally, patients were included who reported up to 8 days of symptoms prior to enrollment. Laboratory data from day 8 produced conflicting results and raises questions regarding the accuracy of symptom recall past one week. These data support the use of earlier enrollment cut-offs with scheduled follow-up visits to monitor the kinetics of certain laboratory findings.

Conclusions
===========

In this study, we sought to characterize DENV infections in a predominantly adult population in Paraguay, focusing on the region with the highest dengue incidence, metro Asunción. This work highlighted clinical, epidemiologic, and laboratory factors that are associated with DENV detection in the acute setting and the potential role of specific antibodies in diagnosis and the progression of disease. Future directions will involve the prospective evaluation of how factors identified in the current study associate with and may predict dengue severity.
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